Skip to main content
Stemline's blood cancer drug accepted under priority review status
8/14/2018

The FDA accepted under priority review Stemline Therapeutics' biologics license application for Elzonris, or tagraxofusp, being developed as a treatment for patients with blastic plasmacytoid dendritic cell neoplasm, with an action date of Feb. 21, 2019. A midstage trial showed that the drug prompted a 54% complete response rate in 13 patients.

Full Story: